查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438192

至 2030 年炭疽菌疫苗市場預測：按疫苗類型、類型、適應症、年齡層、應用、最終用戶和地區進行的全球分析

Anthrax Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type (Live Attenuated Vaccine, Cell Free PA Vaccine and Other Vaccine Types), Type, Disease Indication, Age Group, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球炭疽菌疫苗市場規模為 129 億美元，預計在預測期內將以 6.5% 的年複合成長率成長，到 2030 年達到 202 億美元。

炭疽菌疫苗是一種預防措施，旨在保護個人免受炭疽菌的侵害，這是一種由炭疽菌引起的嚴重細菌感染疾病。炭疽菌可以透過三種型態傳播給人類和其他動物：皮膚、吸入和胃腸道。這種疫苗的開發主要是為了保護軍事相關人員、實驗室工作人員和接觸炭疽菌孢子的高風險族群。此疫苗刺激免疫系統產生針對炭疽菌的保護性抗原成分的抗體。

根據 2021 年 4 月《獸醫世界雜誌》發表的一篇論文，使用固定效應模型從 2452 個樣本中得出，全球炭疽菌盛行率為 28%。在一項隨機效應模型大陸研究中，非洲炭疽菌流行率最高（29%），北美最低（21%）。

炭疽菌流行率增加

炭疽菌市場的盛行率顯著上升，反映出人們對炭疽菌相關風險的日益關注。這種成長增加了對有效疫苗的需求，並刺激了研究和開發的進展。炭疽菌疫情的不斷上升凸顯了採取全面疫苗接種策略並推動市場成長和創新的必要性。然而，對炭疽菌的認知和教育對於公眾健康至關重要，這是推動市場成長的一個因素。

副作用和安全問題

雖然炭疽菌疫苗能有效預防炭疽菌，但它會引起輕微至中度的副作用，例如注射部位疼痛、腫脹和發紅。有些人可能會出現發燒、肌肉酸痛和疲勞。嚴重的過敏反應很少見，但也有可能發生。儘管安全問題包括不利事件的報告，但整體風險效益狀況支持其在接觸炭疽菌的高風險族群中使用。這些都是阻礙市場成長的因素。

技術進步

結合創新的遞送系統和佐劑的下一代疫苗的開發提高了功效和安全性，並且市場正在經歷重大的技術進步。先進的生物技術方法，例如重組 DNA 技術，被用來生產更有效和可擴展的疫苗。此外，配方技術和儲存技術的進步有助於提高穩定性和易於分配。

製造成本高

複雜的製造流程、嚴格的品管措施以及對專業設施的需求導致了高成本。高昂的製造成本不僅影響了疫苗的承受能力，而且對市場准入和廣泛分發構成了挑戰，限制了疫苗向更廣泛人群的可用性。解決這些與成本相關的障礙對於提高炭疽菌疫苗的可用性和可近性至關重要。這些因素正在阻礙因素市場成長。

COVID-19 的影響：

COVID-19 大流行透過醫療保健優先事項和資源的變化間接影響市場。由於注意力和資金被轉移到對抗這場流行病上，炭疽菌的研究和發展可能已被推遲。此外，供應鏈和醫療保健系統的中斷可能會影響製造和分銷。然而，人們對公共衛生和生物防禦的興趣日益濃厚，凸顯了炭疽菌疫苗的重要性，並可能導致人們對疫情後情勢的認知和投資增加。

減毒活病毒疫苗預計將在預測期內成為最大的部分

減毒活病毒疫苗預計將成為預測期內最大的部分。減毒活病毒疫苗炭疽菌疫苗正成為市場上一種有前景的疫苗接種方法。這些疫苗使用減毒版炭疽菌疫苗，可刺激強大的免疫反應，而不會引起疾病。在炭疽菌疫苗市場，由於減毒活病毒疫苗能夠維持長期免疫力，其需求正快速增加。

預計製藥業在預測期內年複合成長率最高

預計製藥業在預測期內的年複合成長率最高。這些設施作為炭疽菌疫苗的分發中心，使個人和醫療保健提供者更容易購買所需的劑量。藥房還透過提供有關疫苗接種時間表、潛在副作用和正確管理的資訊和指導，為公共衛生做出貢獻。藥房參與炭疽菌疫苗市場提高了疫苗的整體供應量，並促進了社區對這種嚴重感染疾病的保護。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。該地區強大的醫療基礎設施和對生物恐怖主義威脅的日益認知正在促進市場擴張。市場主要參與者積極從事研發，以提高疫苗的有效性，進而提高市場競爭力。此外，製藥公司和政府機構之間的策略聯盟正在進一步推動市場動態，並確保炭疽菌疫苗需求的穩定成長。

年複合成長率最高的地區：

預計亞太地區在預測期內將維持最高的年複合成長率。政府促進疫苗接種的努力和醫療基礎設施的進步正在促進市場擴張。該地區的主要公司正在專注於研究和開發，以提高疫苗的有效性。對公共衛生措施和生物恐怖主義事件防備的日益重視也推動了該地區對炭疽菌疫苗的需求。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球炭疽菌疫苗市場：依疫苗類型

  • 減毒活病毒疫苗
  • 無細胞PA疫苗
    • 吸收性炭疽菌疫苗 (AVA)
    • 沉澱炭疽菌疫苗 (AVP)
  • 其他

第6章全球炭疽菌疫苗市場：依類型

  • 次單位疫苗
    • 類毒素疫苗
    • 結合疫苗
    • 重組疫苗
  • 病毒載體疫苗
  • 其他

第7章全球炭疽菌疫苗市場：依適應症分類

  • 病毒性疾病
    • 流感
    • 肝炎
    • 帶狀皰疹
    • 輪狀病毒
    • 其他
  • 細菌疫苗
    • 肺炎球菌疾病
    • 腦膜炎球菌疾病
    • 細菌疫苗
  • 其他

第8章全球炭疽菌疫苗市場：依年齡層別

  • 成人
  • 兒童

第9章全球炭疽菌疫苗市場：依應用分類

  • 對於人類
  • 對於動物
  • 其他

第10章全球炭疽菌疫苗市場：依最終用戶分類

  • 藥局
  • 醫院
  • 其他

第11章全球炭疽菌疫苗市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • AstraZeneca
  • BioNTech SE
  • Colondo Serum Company
  • Emergent Bio Solutions
  • Merck & Co., Inc
  • Moderna Inc.
  • Pfizer Inc
  • Proton Biopharma Ltd
  • Sanofi
  • Seqirus
  • Serum Institute of India Pvt. Ltd
  • ICON plc
Product Code: SMRC25161

According to Stratistics MRC, the Global Anthrax Vaccine Market is accounted for $12.9 billion in 2023 and is expected to reach $20.2 billion by 2030 growing at a CAGR of 6.5% during the forecast period. The Anthrax vaccine is a preventive measure designed to protect individuals from anthrax, a potentially serious bacterial infection caused by the bacterium Bacillus anthracis. Anthrax can affect humans and other animals, and it can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. The vaccine is primarily developed to safeguard military personnel, laboratory workers, and individuals at high risk of exposure to anthrax spores. The vaccine stimulates the immune system to produce antibodies against the protective antigen component of the bacillus anthracis bacterium.

According to an article published in the Veterinary World Journal in April 2021, the prevalence of anthrax globally was 28% from 2452 samples through the fixed effects model. The random effects model's continent-by-subgroup study showed that the pooled prevalence of anthrax was highest in Africa (29%) and lowest in North America (21%).

Market Dynamics:

Driver:

Increase in prevalence of anthrax

The market has witnessed a notable surge in prevalence, reflecting a growing concern for anthrax-related risks. This upswing has heightened demand for effective vaccines, prompting advancements in research and development. The increasing prevalence of anthrax underscores the imperative for comprehensive vaccination strategies, driving market growth and innovation. However, increasing awareness and education about anthrax vaccines is paramount for public health is the factor propelling the growth of the market.

Restraint:

Side effects and safety concerns

The anthrax vaccine, while effective in preventing anthrax, may cause mild to moderate side effects such as pain, swelling, or redness at the injection site. Some individuals may experience fever, muscle aches, or fatigue. Severe allergic reactions are rare but possible. Safety concerns include reports of adverse events, though the overall risk-benefit profile supports its use for those at high risk of anthrax exposure. These are the factors hampering the growth of the market.

Opportunity:

Technological advancements

The market has witnessed significant technological advancements, with the development of next-generation vaccines incorporating innovative delivery systems and adjuvant to enhance efficacy and safety. Advanced biotechnological methods, such as recombinant DNA technology, have been employed to produce more effective and scalable vaccines. Additionally, advancements in formulation and storage technologies contribute to improved stability and ease of distribution.

Threat:

High manufacturing costs

The complex production process, stringent quality control measures, and the need for specialized facilities contribute to elevated expenses. These high manufacturing costs not only impact the affordability of the vaccine but also pose challenges for market accessibility and widespread distribution, limiting its availability to a broader population. Addressing these cost-related barriers is crucial for enhancing the affordability and accessibility of anthrax vaccines. These are the factors hindering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic has indirectly impacted the market, with shifts in healthcare priorities and resources. Attention and funding diverted to combat the pandemic may have slowed Anthrax vaccine research and development. Additionally, disruptions in supply chains and healthcare systems could affect manufacturing and distribution. However, the heightened focus on public health and biodefense may underscore the importance of anthrax vaccines, potentially leading to increased awareness and investment in the post-pandemic landscape.

The live attenuated vaccine segment is expected to be the largest during the forecast period

The live attenuated vaccine segment is expected to be the largest during the forecast period. Live attenuated vaccines for anthrax have gained prominence in the market, offering a promising approach to immunization. Leveraging weakened forms of the anthrax bacterium, these vaccines stimulate a robust immune response without causing the disease. The market for anthrax vaccines is witnessing a notable surge in demand for live attenuated options due to their efficacy in conferring long-lasting immunity.

The pharmacies segment is expected to have the highest CAGR during the forecast period

The pharmacies segment is expected to have the highest CAGR during the forecast period. These establishments serve as distribution points for anthrax vaccines, ensuring that individuals and healthcare providers can easily procure the necessary doses. Pharmacies also contribute to public health by offering information and guidance on vaccination schedules, potential side effects, and proper administration. Their involvement in the Anthrax Vaccine market enhances overall vaccine availability and promotes community protection against this serious infectious disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The region's robust healthcare infrastructure and rising awareness regarding bioterrorism threats contribute to market expansion. Key market players are actively engaged in research and development to enhance vaccine efficacy, fostering market competitiveness. Additionally, strategic collaborations between pharmaceutical companies and government bodies further propel market dynamics, ensuring a steady surge in demand for anthrax vaccines.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Government initiatives promoting vaccination, coupled with advancements in healthcare infrastructure, contribute to market expansion. Key players in the region are focusing on research and development to enhance vaccine efficacy. The growing emphasis on public health measures and preparedness against bioterrorism incidents further propels the demand for anthrax vaccines in the region.

Key players in the market

Some of the key players in Anthrax Vaccine market include AstraZeneca, BioNTech SE, Colondo Serum Company, Emergent Bio Solutions, Merck & Co., Inc, Moderna Inc., Pfizer Inc, Proton Biopharma Ltd, Sanofi, Seqirus, Serum Institute of India Pvt. Ltd and ICON plc.

Key Developments:

In October 2022, ICON plc was selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is currently under clinical trial evaluation.

In June 2022, Emergent BioSolutions Inc. was granted review acceptance of the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) from the US FDA. AV7909 is evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in adults (age group 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

Vaccine Types Covered:

  • Live Attenuated Vaccine
  • Cell Free PA Vaccine
  • Other Vaccine Types

Types Covered:

  • Subunit Vaccines
  • Viral Vector Vaccines
  • Other Types

Disease Indications Covered:

  • Viral Disease
  • Bacterial Vaccine
  • Other Disease Indications

Age Groups Covered:

  • Adult
  • Pediatric

Applications Covered:

  • Human Use
  • Animal Use
  • Other Applications

End Users Covered:

  • Pharmacies
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anthrax Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Live Attenuated Vaccine
  • 5.3 Cell Free PA Vaccine
    • 5.3.1 Anthrax Vaccine Absorbed (AVA)
    • 5.3.2 Anthrax Vaccine Precipitated (AVP)
  • 5.4 Other Vaccine Types

6 Global Anthrax Vaccine Market, By Type

  • 6.1 Introduction
  • 6.2 Subunit Vaccines
    • 6.2.1 Toxoid Vaccines
    • 6.2.2 Conjugate Vaccines
    • 6.2.3 Recombinant vaccines
  • 6.3 Viral Vector Vaccines
  • 6.4 Other Types

7 Global Anthrax Vaccine Market, By Disease Indication

  • 7.1 Introduction
  • 7.2 Viral Disease
    • 7.2.1 Influenza
    • 7.2.2 Hepatitis
    • 7.2.3 Herpes Zoster
    • 7.2.4 Rotavirus
    • 7.2.5 Other Viral Diseases
  • 7.3 Bacterial Vaccine
    • 7.3.1 Pneumococcal Diseases
    • 7.3.2 Meningococcal Diseases
    • 7.3.3 Bacterial Vaccines
  • 7.4 Other Disease Indications

8 Global Anthrax Vaccine Market, By Age Group

  • 8.1 Introduction
  • 8.2 Adult
  • 8.3 Pediatric

9 Global Anthrax Vaccine Market, By Application

  • 9.1 Introduction
  • 9.2 Human Use
  • 9.3 Animal Use
  • 9.4 Other Applications

10 Global Anthrax Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmacies
  • 10.3 Hospitals
  • 10.4 Other End Users

11 Global Anthrax Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AstraZeneca
  • 13.2 BioNTech SE
  • 13.3 Colondo Serum Company
  • 13.4 Emergent Bio Solutions
  • 13.5 Merck & Co., Inc
  • 13.6 Moderna Inc.
  • 13.7 Pfizer Inc
  • 13.8 Proton Biopharma Ltd
  • 13.9 Sanofi
  • 13.10 Seqirus
  • 13.11 Serum Institute of India Pvt. Ltd
  • 13.12 ICON plc

List of Tables

  • Table 1 Global Anthrax Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Anthrax Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 3 Global Anthrax Vaccine Market Outlook, By Live Attenuated Vaccine (2021-2030) ($MN)
  • Table 4 Global Anthrax Vaccine Market Outlook, By Cell Free PA Vaccine (2021-2030) ($MN)
  • Table 5 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Absorbed (AVA) (2021-2030) ($MN)
  • Table 6 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Precipitated (AVP) (2021-2030) ($MN)
  • Table 7 Global Anthrax Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 8 Global Anthrax Vaccine Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Anthrax Vaccine Market Outlook, By Subunit Vaccines (2021-2030) ($MN)
  • Table 10 Global Anthrax Vaccine Market Outlook, By Toxoid Vaccines (2021-2030) ($MN)
  • Table 11 Global Anthrax Vaccine Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 12 Global Anthrax Vaccine Market Outlook, By Recombinant vaccines (2021-2030) ($MN)
  • Table 13 Global Anthrax Vaccine Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 14 Global Anthrax Vaccine Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 15 Global Anthrax Vaccine Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 16 Global Anthrax Vaccine Market Outlook, By Viral Disease (2021-2030) ($MN)
  • Table 17 Global Anthrax Vaccine Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 18 Global Anthrax Vaccine Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 19 Global Anthrax Vaccine Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 20 Global Anthrax Vaccine Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 21 Global Anthrax Vaccine Market Outlook, By Other Viral Diseases (2021-2030) ($MN)
  • Table 22 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccine (2021-2030) ($MN)
  • Table 23 Global Anthrax Vaccine Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 24 Global Anthrax Vaccine Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 25 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccines (2021-2030) ($MN)
  • Table 26 Global Anthrax Vaccine Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 27 Global Anthrax Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 28 Global Anthrax Vaccine Market Outlook, By Adult (2021-2030) ($MN)
  • Table 29 Global Anthrax Vaccine Market Outlook, By Pediatric (2021-2030) ($MN)
  • Table 30 Global Anthrax Vaccine Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Global Anthrax Vaccine Market Outlook, By Human Use (2021-2030) ($MN)
  • Table 32 Global Anthrax Vaccine Market Outlook, By Animal Use (2021-2030) ($MN)
  • Table 33 Global Anthrax Vaccine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 34 Global Anthrax Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Anthrax Vaccine Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 36 Global Anthrax Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 Global Anthrax Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.